Literature DB >> 12972038

Donor cell replacement in mice transplanted in utero is limited by immune-independent mechanisms.

J E Barker1, A J T Schuldt, M D Lessard, C D Jude, C A Vogler, B W Soper.   

Abstract

In utero transplantation (IUTx) therapy with allogeneic cells results in negligible peripheral blood (PBL) chimerism in nonablated humans with progressive diseases. IUTx has been successful only in immunocompromised fetuses. Because early treatment has great potential for halting disease progression, mechanisms preventing cell expansion must be identified and corrected. The hypothesis that factors in addition to allogenicity are responsible for low-level expansion is tested here by transplanting congenic cells into nonablated normal and mucopolycaccharidosis type VII (MPSVII) murine fetuses. MPSVII mice lack the enzyme beta-glucuronidase (GUSB-), accumulate glycosaminoglycans, and progressively develop severe storage disease. Low levels of enzyme can reverse storage. Evidence presented elsewhere showed that allogeneic donor cells overexpressing GUSB are negligible and their corrective effects are lost post-IUTx in MPSVII mice. We find that (1) congenic donor PBL cells, like allogeneic cells, are negligible in PBL of normal GUSB+ and MPSVII GUSB- hosts post-IUTx; (2) congenic, unlike allogeneic cells, are retained long term in both GUSB+ and GUSB- recipients; and (3) sufficient GUSB is produced to alleviate storage for up to 11.5 months in multiple tissues of GUSB- hosts. GUSB+ and GUSB- animals repopulate to a similar extent, indicating that donor GUSB enzyme does not initiate an immune response in the MPSVII null recipients. We conclude that the initial expansion of congenic and allogeneic cells is limited post-IUTx by non-immune-related mechanisms and the level of PBL cells is not necessarily indicative of graft failure following congenic IUTx. The mechanism limiting initial expansion may differ from that supporting long-term cell retention.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12972038     DOI: 10.1016/s1079-9796(03)00134-7

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  6 in total

1.  Evidence for an immune barrier after in utero hematopoietic-cell transplantation.

Authors:  William H Peranteau; Masayuki Endo; Obinna O Adibe; Alan W Flake
Journal:  Blood       Date:  2006-10-05       Impact factor: 22.113

2.  In utero transplanted human hepatocytes allow postnatal engraftment of human hepatocytes in pigs.

Authors:  James E Fisher; Joseph B Lillegard; Travis J McKenzie; Brian R Rodysill; Peter J Wettstein; Scott L Nyberg
Journal:  Liver Transpl       Date:  2013-03       Impact factor: 5.799

3.  Maternal alloantibodies induce a postnatal immune response that limits engraftment following in utero hematopoietic cell transplantation in mice.

Authors:  Demetri J Merianos; Eleonor Tiblad; Matthew T Santore; Carlyn A Todorow; Pablo Laje; Masayuki Endo; Philip W Zoltick; Alan W Flake
Journal:  J Clin Invest       Date:  2009-08-03       Impact factor: 14.808

4.  Partial rescue of mucopolysaccharidosis type VII mice with a lifelong engraftment of allogeneic stem cells in utero.

Authors:  Norimasa Ihara; Umezawa Akihiro; Naoko Onami; Hideki Tsumura; Eisuke Inoue; Satoshi Hayashi; Haruhiko Sago; Shuki Mizutani
Journal:  Congenit Anom (Kyoto)       Date:  2015-02       Impact factor: 1.409

Review 5.  Experimental and clinical progress of in utero hematopoietic cell transplantation therapy for congenital disorders.

Authors:  Chunyu Shi; Lu Pan; Zheng Hu
Journal:  Front Pharmacol       Date:  2022-09-02       Impact factor: 5.988

6.  In utero hepatocellular transplantation in rats.

Authors:  Emma Muñoz-Sáez; Estefanía de Munck; Paloma Maganto; Cristina Escudero; Begoña G Miguel; Rosa María Arahuetes
Journal:  Clin Dev Immunol       Date:  2013-08-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.